The fees associated with clinical research (including chart review studies) that are funded in whole or in part by industry sponsors (regardless of authorship of the protocol) will be increasing effective January 1, 2026. Please review the chart carefully for budgeting purposes as there are additional charges that were added as a result of benchmarking with other institutions. Note that this is different than budgeting for Pitt as the IRB of Record. Please contact irb.reliance@pitt.edu for information regarding sIRB fees.
| Review Process | Project Type | New Fee Beginning 1/1/26 |
|---|---|---|
| Full Board or Expedited | Initial Review | $3000 |
| Full Board | Continuing Review | $2000 |
| Expedited | Continuing Review | $1500 |
| Full Board or Expedited | Study-Wide Sponsor Initiated Amendment | $1000 |
| Exempt | Initial Review | $500 |
| All Review Types | Study Close-Out | $600 |
| Ceded Studies Reviewed by a Commerial IRB | One-time Administrative Fee (in addition to IRB fees charged by the commercial IRB) |
$2500 |
Studies that are subject to the IRB review fees will not be processed until the fees are paid in full. There may be circumstances when investigators can request a waiver of the fee. The most common reason for waiver is when the industry collaborator is not funding the entire study but is supporting the study by providing only the drug or other nominal support.
For studies approved prior to January 1, 2026, the previous fee structure should be utilized. The fees in effect at the time of Initial IRB Review will be applied in perpetuity, for the life of the project. If the Initial Approval date is 1/1/26 or after, then the rates above apply.
If you have any questions regarding this change, please contact us at askirb@pitt.edu.